Literature DB >> 3155453

Methionine-enkephalin and beta-endorphin levels in brain, pancreas, and adrenals of db/db mice.

J Greenberg, F Ellyin, G Pullen, S Ehrenpreis, S P Singh, J Cheng.   

Abstract

Levels of methionine-enkephalin immunoreactivity (MEI) and beta-endorphin immunoreactivity (BEI) were measured by means of a specific RIA in pituitary, hypothalamus, pancreas, and adrenal glands of db/db and control mice. We found significantly higher levels of MEI in the pituitaries of db/db mice than in either littermate or background strain controls. There was no significant difference in MEI levels in pancreas, adrenal glands, and hypothalamus. There was a significant difference in the BEI levels in the pituitaries of db/db mice compared with those in controls. No significant difference in BEI levels was observed between db/db and control mice in any of the other regions examined. We conclude from the above data that the opiate peptide system in the hypophyseal-hypothalamic axis of the db/db mouse is abnormal and warrants further investigation. The significance of this finding with respect to the possible etiology of diabetes mellitus is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155453     DOI: 10.1210/endo-116-1-328

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Immunocytochemical detection of peptides in the guinea pig cochlea.

Authors:  R Nowak; A Dorn; H G Bernstein; A Rinne; H J Scholtz; M Ziegler
Journal:  Arch Otorhinolaryngol       Date:  1986

2.  The rate of degradation of liver glycogen phosphorylase is specifically decreased in the C57BL/KsJ-db/db mouse.

Authors:  W J Roesler; M S Nijjar; R L Khandelwal
Journal:  Mol Cell Biochem       Date:  1989-06-01       Impact factor: 3.396

Review 3.  Opioid peptides and glucose metabolism.

Authors:  A Lala; P Bouloux; G Tamburrano; E Gale
Journal:  J Endocrinol Invest       Date:  1987-02       Impact factor: 4.256

Review 4.  Opioid peptides and metabolic regulation.

Authors:  D Giugliano; R Torella; P J Lefèbvre; F D'Onofrio
Journal:  Diabetologia       Date:  1988-01       Impact factor: 10.122

5.  Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits.

Authors:  I S Zagon; Joseph W Sassani; Melissa A Carroll; Patricia J McLaughlin
Journal:  Brain Res Bull       Date:  2009-10-21       Impact factor: 4.077

Review 6.  Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Matthew S Klocek; Ian S Zagon
Journal:  Brain Res Bull       Date:  2009-08-14       Impact factor: 4.077

Review 7.  Opioids and behavior: genetic aspects.

Authors:  H R Frischknecht; B Siegfried; P G Waser
Journal:  Experientia       Date:  1988-06-15

Review 8.  The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes-The Lorenz E. Zimmerman Tribute Lecture.

Authors:  Joseph W Sassani; Patricia J Mc Laughlin; Ian S Zagon
Journal:  J Diabetes Res       Date:  2016-09-14       Impact factor: 4.011

9.  Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Michelle B Titunick; Ian S Zagon
Journal:  BMC Ophthalmol       Date:  2019-01-28       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.